Related references
Note: Only part of the references are listed.Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study
Ohad Atia et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2023)
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis
Dana Lukin et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
Vedolizumab Immunogenicity With Long-Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease
Timothy Wyant et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Infliximab and its biosimilar produced similar first-year therapy outcomes in patients with inflammatory bowel disease
Anne Nikkonen et al.
ACTA PAEDIATRICA (2020)
The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Sudabeh Alatab et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Vedolizumab Trough Levels in Children With Anti-Tumor Necrosis Factor Refractory Inflammatory Bowel Disease
Martine A. Aardoom et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2020)
Concentration of fecal calprotectin in 11,255 children aged 0-18 years
Kaija-Leena Kolho et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2020)
Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel disease
Nikolas Plevris et al.
FRONTLINE GASTROENTEROLOGY (2020)
Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease
Ryan C. Ungaro et al.
JOURNAL OF CROHNS & COLITIS (2019)
Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease
Jurij Hanzel et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2019)
The Role of Early Biologic Therapy in Inflammatory Bowel Disease
Dana Rachel Berg et al.
INFLAMMATORY BOWEL DISEASES (2019)
Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease
Sebastian Zeissig et al.
GUT (2019)
Associations Among Mucosal and Transmural Healing and Fecal Level of Calprotectin in Children With Crohn's Disease
Inbar Weinstein-Nakar et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease
Elisa K. Boden et al.
DIGESTIVE DISEASES AND SCIENCES (2018)
Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD
Christoffer Soendergaard et al.
BMJ OPEN GASTROENTEROLOGY (2018)
Long-term Efficacy of Vedolizumab for Ulcerative Colitis
Edward V. Loftus et al.
JOURNAL OF CROHNS & COLITIS (2017)
Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN
Oren Ledder et al.
JOURNAL OF CROHNS & COLITIS (2017)
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
Siew C. Ng et al.
LANCET (2017)
Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease
Anna-Maija Puolanne et al.
DIGESTIVE DISEASES AND SCIENCES (2017)
β7-Integrin exacerbates experimental DSS-induced colitis in mice by directing inflammatory monocytes into the colon
A. Schippers et al.
MUCOSAL IMMUNOLOGY (2016)
Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease
Namita Singh et al.
INFLAMMATORY BOWEL DISEASES (2016)
Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease
Maire A. Conrad et al.
INFLAMMATORY BOWEL DISEASES (2016)
How effective is the use of long-term anti-TNF for paediatric IBD? Clues from real-life surveillance cohorts
Chani Topf-Olivestone et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2015)
Localization of dendritic cells in the gut epithelium requires MAdCAM-1
Thomas Clahsen et al.
CLINICAL IMMUNOLOGY (2015)
Effects of Vedolizumab Induction Therapy for Patients With Crohn's Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
Bruce E. Sands et al.
GASTROENTEROLOGY (2014)
The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease
Kaija-Leena Kolho et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2014)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents
Pauliina Molander et al.
INFLAMMATORY BOWEL DISEASES (2012)
Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels
Anssi Hamalainen et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease
Kaija-Leena Kolho et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2006)
Share Paper
